ClinicalTrials.gg
Active, not recruitingNCT04658147Updated Oct 28, 2026Results posted

Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma

A Phase 1 interventional study of Nivolumab and Relatlimab in Hepatocellular Carcinoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Phase 1, Interventional, and Treatment

How we know · 5 judgments

Updated Oct 28, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 53 studies testing nivolumab in Carcinoma, Hepatocellular — 11 open to participants now, 17 under way, 1 of them phase 3. Nivolumab · Carcinoma, Hepatocellular.

Enrollment
32nd of 53
31 · median 40
Started
2021
with 4 others
Phase 1
12 of 53
2 open now
Primary completion
2025-09
later than 3 of 16 live
Registered
37th of 53
by date
Lead sponsor
2 of 53
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Among the 53 studies testing nivolumab in Carcinoma, Hepatocellular, this one is the 32nd largest by enrollment, is one of 5 that started in 2021, is one of 12 in phase 1, reaches primary completion later than 3 of the 16 other live ones, and was the 37th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

11 of the 53 studies testing nivolumab in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing nivolumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and feasibility of neoadjuvant/adjuvant Nivolumab or Nivolumab plus Relatlimab in patients with HCC.

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • Relatlimab
  • Nivolumab
  • Immunotherapy
  • Anti PD-1
  • Anti - LAG-3
  • Resectable hepatocellular Cancer
  • Potentially resectable hepatocellular Cancer
  • Hepatocellular Cancer (HCC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Technically resectable HCC as defined by:

    • HCC may be diagnosed pathologically, or noninvasively by the American Association for the Study of Liver Diseases (AASLD) criteria or the Organ Procurement and Transplant Network (OPTN) Obligatory Diagnostic Criteria for Hepatocellular Carcinoma (HCC).
    • No extrahepatic spread, no nodal disease, and no bilateral left and right branch portal vein involvement.
  • per 1.1 as determined by the investigator.
  • Age ≥ 18 years old on the day of consent.
  • performance status ≤1 or ≥80.
  • Patients must have adequate organ and marrow function defined by study-specified laboratory tests prior to initial study drug.
  • Patients must have adequate liver remnant and function.
  • Antiviral therapy per local standard of care for .
  • assessment with documented LVEF ≥ 50% by either TTE or MUGA (TTE preferred) within 6 months from first study drug administration.
  • Woman of must have a negative pregnancy test.
  • Must use acceptable form of while on study.
  • Ability to understand and willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  • Fibrolamellar carcinoma or mixed HCC.
  • Receiving, or previously received, any systemic chemotherapy, or agent for HCC.
  • Patients with a history of prior treatment with , anti-PD-L1, anti-PD-L2, anti-CTLA4, or anti-Lag-3 antibodies.
  • Has a known additional that is expected to require active treatment within two years, or is likely to be life-limiting in the opinion of the treating investigator. Superficial bladder cancer, non-melanoma skin cancers, or low grade prostate cancer not requiring therapy would not exclude participation in this trial.
  • History of infection.
  • Active co-infection with and HDV.
  • Has a diagnosis of immunodeficiency, or is receiving systemic therapy.
  • Prior tissue or organ allograft or bone marrow transplantation.
  • History of any disease requiring systemic treatment within the past 2 years.
  • Systemic or topical corticosteroids at doses (> 10 mg/day of prednisone or equivalent).
  • Confirmed history of encephalitis, meningitis, or uncontrolled seizures in the year prior to .
  • Uncontrolled intercurrent illness.•
  • Uncontrolled or significant cardiovascular disease.
  • Significant heart disease.
  • Moderate or severe ascites.
  • Known or suspected to study treatment.
  • Are pregnant or breastfeeding.
  • and men with female partners (WOCBP) who are not willing to use .
  • Unable to have blood drawn.
  • Any other sound medical, psychiatric, and/or social reason as determined by the Investigator.
  • Any illicit drugs or other substance abuse.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Arm A - Nivolumab

    Participants receive Nivolumab only.

    Drug: Nivolumab

  • Experimental
    Arm B - Nivolumab and Relatlimab

    Participants receive Nivolumab and Relatlimab.

    Drug: Nivolumab · Drug: Relatlimab

Interventions

  • Patients received 480mg Nivolumab as a 30 minute IV infusion on Day 1 of Cycles 1 and 2 (28 day cycles) prior to surgery. Post-surgery, patients received an additional 10 doses of adjuvant 480mg Nivolumab therapy on Day 1 of each cycle (every 28 days).

    Also known as: OPDIVO™, BMS 936558, MDX1106, ONO-4538

  • Patients received either 480mg or 960mg Relatlimab as a 30 minute IV infusion on Day 1 of Cycles 1 and 2 (28 day cycles) prior to surgery. Post-surgery, patients received an additional 10 doses of adjuvant 480mg or 960mg Relatlimab therapy on Day 1 every 28 days. Dosing was changed from 960mg to 480mg based on guidance from Bristol Myers Squibb.

    Also known as: BMS-986016, BMS-986016-01, Anti-LAG-3

06

What researchers measure

Primary outcomes

  1. Number of Patients Precluded From Surgery

    Number of patients that experienced a treatment-related adverse event that precludes continuing on to surgery within 60 days of the last dose of neoadjuvant treatment. Individuals who do not go on to receive surgery due to other causes (e.g. progressive disease, patient refusal) will not be counted as feasibility failures.

    Time frame: Up to 2 months

Secondary outcomes

  1. Number of Participants Experiencing Grade 3 or Above Study Drug-related Adverse Event (AE)

    When calculating the incidence of AEs, each AE (as defined by NCI CTCAE v5.0) will be counted only once for a given subject.

    Time frame: Up to 15 months

  2. Number of Participants Who Obtain R0 Resection

    Number of evaluable participants who obtain R0 resection. R0 resection rate will be estimated among the patients who receive at least one dose of neoadjuvant treatment and went to surgery. R0 resection is defined by a microscopically margin-negative resection, in which no tumor (gross or microscopic) remains in the primary tumor bed.

    Time frame: Up to 2 months

  3. Number of Evaluable Patients With Pathologic Response to Treatment

    Pathologic response includes pathologic complete response (pCR) or major pathologic responses (MPR). Pathologic response will be evaluated in patients who receive at least one dose of study drug and receive surgery.

    Time frame: Up to 2 months

  4. Objective Response Rate (ORR) at 8 Weeks Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1).

    Objective response rate (ORR) is defined as the number of patients achieving a complete response (CR) or partial response (PR) based on RECIST 1.1at 8 weeks. CR = Disappearance af all target lesions, PR = \>30% decrease in the sum of diameters of target lesions. Participants who discontinue due to toxicity or clinical progression prior to post-baseline tumor assesment will be considered as non-responders. Participants who discontinue for other reasons prior to their first dose of study drug will not be included in the analysis.

    Time frame: 8 weeks

  5. Overall Survival (OS) Rate at 12 Months

    OS rate is defined as the proportion of patients who are alive at 12 months. Estimation based on the Kaplan-Meier curve.

    Time frame: 12 months

  6. Overall Survival (OS) Rate at 18 Months

    OS rate is defined as the proportion of patients who are alive at 18 months. Estimation based on the Kaplan-Meier curve.

    Time frame: 18 months

  7. Overall Survival (OS) at 3 Years

    OS rate is defined as the proportion of patients who are alive at 3 years. Estimation based on the Kaplan-Meier curve.

    Time frame: 3 years

  8. Overall Survival (OS) at 5 Years

    OS rate is defined as the proportion of patients who are alive at 12 months. Estimation based on the Kaplan-Meier curve.

    Time frame: 5 years

  9. Disease Free Survival (DFS) Rate at 12 Months

    The 12 months DFS rate is defined as the Kaplan-Meier estimate of the proportion of patients alive and free of disease recurrence at 12 months from date of definitive freedom of disease. Patients who did not experience disease-free status were excluded from this calculation.

    Time frame: 12 months

  10. Disease Free Survival (DFS) at 18 Months

    The 18 months DFS rate is defined as the Kaplan-Meier estimate of the proportion of patients alive and free of disease recurrence at 18 months from date of definitive freedom of disease. Patients who did not experience disease-free status were excluded from this calculation.

    Time frame: 18 months

  11. Disease Free Survival (DFS) at 3 Years

    The 3 years DFS rate is defined as the Kaplan-Meier estimate of the proportion of patients alive and free of disease recurrence at 3 years from date of definitive freedom of disease. Patients who did not experience disease-free status were excluded from this calculation.

    Time frame: 3 years

  12. Disease Free Survival (DFS) at 5 Years

    The 5 years DFS rate is defined as the Kaplan-Meier estimate of the proportion of patients alive and free of disease recurrence at 5 years from date of definitive freedom of disease. Patients who did not experience disease-free status were excluded from this calculation.

    Time frame: 5 years

  13. Overall Survival (OS)

    Median OS will be measured from date of randomization or eligibility confirmation until death or end of follow-up. OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis. Estimation based on the Kaplan-Meier curve.

    Time frame: 6 years

  14. Disease Free Survival (DFS)

    Median DFS is defined as the duration of time from date of randomization or eligibility confirmation to the date of disease progression precluding surgery, disease progression or recurrence at or after surgery, or death, whichever occurs first. Patients will be censored at date of last scan, unless they developed a second, unrelated primary tumor, in which they will be censored at the last scan prior to cancer-directed therapy for the second tumor. Estimation based on the Kaplan-Meier curve.

    Time frame: Up to 57 months

07

Results

Posted Oct 28, 2026

Participant flow

Participant flow — Overall Study
MilestoneArm A - NivolumabArm B - Nivolumab and Relatlimab
Started1615
Completed1515
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryNumber of Patients Precluded From Surgery

Number of patients that experienced a treatment-related adverse event that precludes continuing on to surgery within 60 days of the last dose of neoadjuvant treatment. Individuals who do not go on to receive surgery due to other causes (e.g. progressive disease, patient refusal) will not be counted as feasibility failures.

Time frame:
Up to 2 months
Reported as:
Count of participants · Participants
Number of Patients Precluded From Surgery
ParticipantsArm A - NivolumabArm B - Nivolumab and Relatlimab
Number of Patients Precluded From Surgery00
SecondaryNumber of Participants Experiencing Grade 3 or Above Study Drug-related Adverse Event (AE)

When calculating the incidence of AEs, each AE (as defined by NCI CTCAE v5.0) will be counted only once for a given subject.

Time frame:
Up to 15 months
Reported as:
Count of participants · Participants
Number of Participants Experiencing Grade 3 or Above Study Drug-related Adverse Event (AE)
ParticipantsArm A - NivolumabArm B - Nivolumab and Relatlimab
Number of Participants Experiencing Grade 3 or Above Study Drug-related Adverse Event (AE)44
SecondaryNumber of Participants Who Obtain R0 Resection

Number of evaluable participants who obtain R0 resection. R0 resection rate will be estimated among the patients who receive at least one dose of neoadjuvant treatment and went to surgery. R0 resection is defined by a microscopically margin-negative resection, in which no tumor (gross or microscopic) remains in the primary tumor bed.

Time frame:
Up to 2 months
Reported as:
Count of participants · Participants
Number of Participants Who Obtain R0 Resection
ParticipantsArm A - NivolumabArm B - Nivolumab and Relatlimab
Number of Participants Who Obtain R0 Resection1311
SecondaryNumber of Evaluable Patients With Pathologic Response to Treatment

Pathologic response includes pathologic complete response (pCR) or major pathologic responses (MPR). Pathologic response will be evaluated in patients who receive at least one dose of study drug and receive surgery.

Time frame:
Up to 2 months
Reported as:
Count of participants · Participants
Number of Evaluable Patients With Pathologic Response to Treatment
ParticipantsArm A - NivolumabArm B - Nivolumab and Relatlimab
Number of Evaluable Patients With Pathologic Response to Treatment34
SecondaryObjective Response Rate (ORR) at 8 Weeks Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1).

Objective response rate (ORR) is defined as the number of patients achieving a complete response (CR) or partial response (PR) based on RECIST 1.1at 8 weeks. CR = Disappearance af all target lesions, PR = \>30% decrease in the sum of diameters of target lesions. Participants who discontinue due to toxicity or clinical progression prior to post-baseline tumor assesment will be considered as non-responders. Participants who discontinue for other reasons prior to their first dose of study drug will not be included in the analysis.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Objective Response Rate (ORR) at 8 Weeks Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1).
ParticipantsArm A - NivolumabArm B - Nivolumab and Relatlimab
Objective Response Rate (ORR) at 8 Weeks Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1).23
SecondaryOverall Survival (OS) Rate at 12 Months

OS rate is defined as the proportion of patients who are alive at 12 months. Estimation based on the Kaplan-Meier curve.

Time frame:
12 months
Reported as:
Number · Percentage of participants
Overall Survival (OS) Rate at 12 Months
Percentage of participantsArm A - NivolumabArm B - Nivolumab and Relatlimab
Overall Survival (OS) Rate at 12 Months86.7 (71.1 to 100)93.3 (81.5 to 100)
SecondaryOverall Survival (OS) Rate at 18 Months

OS rate is defined as the proportion of patients who are alive at 18 months. Estimation based on the Kaplan-Meier curve.

Time frame:
18 months
Reported as:
Number · Percentage of participants
Overall Survival (OS) Rate at 18 Months
Percentage of participantsArm A - NivolumabArm B - Nivolumab and Relatlimab
Overall Survival (OS) Rate at 18 Months72 (51.9 to 99.8)86.2 (70.0 to 100)
SecondaryOverall Survival (OS) at 3 Years

OS rate is defined as the proportion of patients who are alive at 3 years. Estimation based on the Kaplan-Meier curve.

Time frame:
3 years
Reported as:
Number · Percentage of participants
Overall Survival (OS) at 3 Years
Percentage of participantsArm A - NivolumabArm B - Nivolumab and Relatlimab
Overall Survival (OS) at 3 Years53.3 (31.2 to 91.2)86.2 (70.0 to 100)
SecondaryOverall Survival (OS) at 5 Years

OS rate is defined as the proportion of patients who are alive at 12 months. Estimation based on the Kaplan-Meier curve.

Time frame:
5 years

Results for this outcome have not been posted.

SecondaryDisease Free Survival (DFS) Rate at 12 Months

The 12 months DFS rate is defined as the Kaplan-Meier estimate of the proportion of patients alive and free of disease recurrence at 12 months from date of definitive freedom of disease. Patients who did not experience disease-free status were excluded from this calculation.

Time frame:
12 months
Reported as:
Number · Percentage of participants
Disease Free Survival (DFS) Rate at 12 Months
Percentage of participantsArm A - NivolumabArm B - Nivolumab and Relatlimab
Disease Free Survival (DFS) Rate at 12 Months75 (54.1 to 100)100 (100 to 100)
SecondaryDisease Free Survival (DFS) at 18 Months

The 18 months DFS rate is defined as the Kaplan-Meier estimate of the proportion of patients alive and free of disease recurrence at 18 months from date of definitive freedom of disease. Patients who did not experience disease-free status were excluded from this calculation.

Time frame:
18 months
Reported as:
Number · Percentage of participants
Disease Free Survival (DFS) at 18 Months
Percentage of participantsArm A - NivolumabArm B - Nivolumab and Relatlimab
Disease Free Survival (DFS) at 18 Months75.0 (54.1 to 100)90.0 (73.2 to 100)
SecondaryDisease Free Survival (DFS) at 3 Years

The 3 years DFS rate is defined as the Kaplan-Meier estimate of the proportion of patients alive and free of disease recurrence at 3 years from date of definitive freedom of disease. Patients who did not experience disease-free status were excluded from this calculation.

Time frame:
3 years
Reported as:
Number · Percentage of participants
Disease Free Survival (DFS) at 3 Years
Percentage of participantsArm A - NivolumabArm B - Nivolumab and Relatlimab
Disease Free Survival (DFS) at 3 Years64.3 (41.2 to 100)75 (49.6 to 100)
SecondaryDisease Free Survival (DFS) at 5 Years

The 5 years DFS rate is defined as the Kaplan-Meier estimate of the proportion of patients alive and free of disease recurrence at 5 years from date of definitive freedom of disease. Patients who did not experience disease-free status were excluded from this calculation.

Time frame:
5 years

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)

Median OS will be measured from date of randomization or eligibility confirmation until death or end of follow-up. OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis. Estimation based on the Kaplan-Meier curve.

Time frame:
6 years

Results for this outcome have not been posted.

SecondaryDisease Free Survival (DFS)

Median DFS is defined as the duration of time from date of randomization or eligibility confirmation to the date of disease progression precluding surgery, disease progression or recurrence at or after surgery, or death, whichever occurs first. Patients will be censored at date of last scan, unless they developed a second, unrelated primary tumor, in which they will be censored at the last scan prior to cancer-directed therapy for the second tumor. Estimation based on the Kaplan-Meier curve.

Time frame:
Up to 57 months
Reported as:
Median · Months
Disease Free Survival (DFS)
MonthsArm A - NivolumabArm B - Nivolumab and Relatlimab
Disease Free Survival (DFS)36.49 (18.18 to NA)NA (26.20 to NA)

Adverse events

Collected over Serious and Other (Not Including Serious) Adverse Events were evaluated from start of treatment up to 15 months. All-cause mortality was evaluated from start of treatment up to 59 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A - Nivolumab6/15 (40%)3/15 (20%)14/15 (93.3%)
Arm B - Nivolumab and Relatlimab2/15 (13.3%)2/15 (13.3%)15/15 (100%)
Most frequent serious events
Most frequent serious events
EventArm A - NivolumabArm B - Nivolumab and Relatlimab
Acute kidney injuryRenal and urinary disorders1/150/15
ColitisGastrointestinal disorders0/151/15
DysphagiaGastrointestinal disorders1/150/15
FractureInjury, poisoning and procedural complications1/150/15
Generalized edemaGeneral disorders1/150/15
MyocarditisCardiac disorders0/151/15
MyositisMusculoskeletal and connective tissue disorders0/151/15
SyncopeNervous system disorders1/150/15
Most frequent other events
Showing 10 of 85
Most frequent other events
EventArm A - NivolumabArm B - Nivolumab and Relatlimab
Weight lossInvestigations8/158/15
HypothyroidismEndocrine disorders0/155/15
Rash maculo-papularSkin and subcutaneous tissue disorders1/155/15
Back painMusculoskeletal and connective tissue disorders2/154/15
Dry mouthGastrointestinal disorders0/154/15
FatigueGeneral disorders4/154/15
HypertensionVascular disorders4/152/15
HyperthyroidismEndocrine disorders0/154/15
Abdominal painGastrointestinal disorders3/153/15
AnorexiaMetabolism and nutrition disorders3/153/15

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm A - NivolumabArm B - Nivolumab and RelatlimabTotal
<=18 years000
Between 18 and 65 years3912
>=65 years12618
Sex: Female, Male
Sex: Female, Male(Participants)Arm A - NivolumabArm B - Nivolumab and RelatlimabTotal
Female5611
Male10919
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A - NivolumabArm B - Nivolumab and RelatlimabTotal
American Indian or Alaska Native000
Asian224
Native Hawaiian or Other Pacific Islander000
Black or African American617
White71219
More than one race000
Unknown or Not Reported000
08

Study locations

2 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Sep 2025, 51 months.

Results were first posted in Oct 2026, 1 year 1 month after primary completion.

Of 147 non-industry phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 80. This study's 51 months is close to that.

Counting every sponsor, half of 250 studies reached it within 49 months; a quarter within 32 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2020
First posted
Dec 8, 2020
StartActual
May 28, 2021
Primary completionActual
Sep 2, 2025
CompletionEst.
Jun 1, 2030
Results first posted
Oct 28, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 28, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Number of patients who complete pre-op treatment and proceed to surgeryNow Number of Patients Precluded From SurgeryTime frame: 4 years → Up to 2 months
Oct 28, 2026
Documents
Secondary outcomes
11 edited, 3 added, 1 removed
What changed in the outcomes
  • EditedNumber of participants experiencing study drugParticipants Experiencing Grade 3 or Above Study Drug-related toxicitiesAdverse Event (AE)Time frame: 4 years → Up to 15 months
  • EditedPercentageNumber of participants who obtainParticipants Who Obtain R0 resectionResectionTime frame: 8 weeks → Up to 2 months
  • EditedObjective response rateResponse Rate (ORR) at 8 weeksWeeks Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1).Time frame: 8 weeks
  • EditedOverall survivalSurvival (OS) Rate at 12 monthsMonthsTime frame: 12 months
  • EditedOverall survivalSurvival (OS) Rate at 18 monthsMonthsTime frame: 18 months
  • EditedOverall survivalSurvival (OS) at 3 yearsYearsTime frame: 3 years
  • EditedOverall survivalSurvival (OS) at 5 yearsYearsTime frame: 5 years
  • EditedDisease free survivalFree Survival (DFS) Rate at 12 monthsMonthsTime frame: 12 months
  • EditedDisease free survivalFree Survival (DFS) at 18 monthsMonthsTime frame: 18 months
  • EditedDisease free survivalFree Survival (DFS) at 3 yearsYearsTime frame: 3 years
  • EditedDisease free survivalFree Survival (DFS) at 5 yearsYearsTime frame: 5 years
  • AddedNumber of Evaluable Patients With Pathologic Response to TreatmentTime frame: Up to 2 months
  • AddedOverall Survival (OS)Time frame: 6 years
  • AddedDisease Free Survival (DFS)Time frame: Up to 57 months
  • RemovedPercentage of evaluable patients who obtain a pathologic complete response (pCR) or major pathologic response (MPR)Time frame: 8 weeks
Oct 28, 2026
Title
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Number of patients who complete pre-op treatment and proceed to surgeryNow Number of Patients Precluded From SurgeryTime frame: 4 years → Up to 2 months
    Secondary outcomes 11 edited, 3 added, 1 removed
    What changed in the outcomes
    • EditedNumber of participants experiencing study drugParticipants Experiencing Grade 3 or Above Study Drug-related toxicitiesAdverse Event (AE)Time frame: 4 years → Up to 15 months
    • EditedPercentageNumber of participants who obtainParticipants Who Obtain R0 resectionResectionTime frame: 8 weeks → Up to 2 months
    • EditedObjective response rateResponse Rate (ORR) at 8 weeksWeeks Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1).Time frame: 8 weeks
    • EditedOverall survivalSurvival (OS) Rate at 12 monthsMonthsTime frame: 12 months
    • EditedOverall survivalSurvival (OS) Rate at 18 monthsMonthsTime frame: 18 months
    • EditedOverall survivalSurvival (OS) at 3 yearsYearsTime frame: 3 years
    • EditedOverall survivalSurvival (OS) at 5 yearsYearsTime frame: 5 years
    • EditedDisease free survivalFree Survival (DFS) Rate at 12 monthsMonthsTime frame: 12 months
    • EditedDisease free survivalFree Survival (DFS) at 18 monthsMonthsTime frame: 18 months
    • EditedDisease free survivalFree Survival (DFS) at 3 yearsYearsTime frame: 3 years
    • EditedDisease free survivalFree Survival (DFS) at 5 yearsYearsTime frame: 5 years
    • AddedNumber of Evaluable Patients With Pathologic Response to TreatmentTime frame: Up to 2 months
    • AddedOverall Survival (OS)Time frame: 6 years
    • AddedDisease Free Survival (DFS)Time frame: Up to 57 months
    • RemovedPercentage of evaluable patients who obtain a pathologic complete response (pCR) or major pathologic response (MPR)Time frame: 8 weeks
    Title Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
    + 6 other changes: index terms, verification date, description, arm descriptions, criteria formatting and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04658147
Responsible party
Sponsor
First posted
Dec 8, 2020
Start date
May 28, 2021
Primary completion
Sep 2, 2025
Completion
Jun 1, 2030 (estimated)
Results posted
Oct 28, 2026
Last update
Oct 28, 2026

Study contacts

Mark Yarchoan, MD
principal investigator · SKCCC Johns Hopkins Medical Institution

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion